ICD-11 vs. ICD-10 – a review of updates and novelties introduced in the latest version of the WHO International Classification of Diseases

Krawczyk, Piotr; Święcicki, Łukasz

doi:10.12740/pp/103876

Cited by 46 publications

(31 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An observational study was conducted in different hospitals in western India to evaluate the effect of combined drug on various parameters like body weight, blood glucose and lipid profile for assessing the metabolic syndrome. A total of 273 subjects were screened based on the age, sex and diagnostic criteria (ICD-10 classification) [12] for schizophrenia and schizo-affective disorder. Patients already suffering from diabetes mellitus, hypertension, hyperlipidaemia and obesity with other antipsychotic drug were excluded from the study.…”

Section: Methodsmentioning

confidence: 99%

The Prevalence of Metabolic Syndrome of Patients on Treatment with Haloperidol and Risperidone or Olanzapine

Suresh

Lakhani²,

Shah

et al. 2021

JPRI

View full text Add to dashboard Cite

Background: The background of the work stems from the observation due to the prevalence of antipsychotic drugs in causing metabolic disorder. The metabolic disorder is one of the major concern of antipsychotic drugs for schizophrenic patients. The present study is mainly aimed to establish the role of haloperidol and risperidone or olanzapine in causing metabolic syndrome of schizophrenic patients. Methods: Sixty-four schizophrenic patients were divided into two groups. First and second group received haloperidol and risperidone or olanzapine respectively for three months. Body mass index, random blood sugar and lipid profile were investigated before and after the treatment. Results: Both groups of schizophrenic patients have shown a significant increase in the BMI, random blood sugar and lipid profile indicating a propensity to cause metabolic disorder. Conclusion: From the present study it is concluded that there is a high prevalence of metabolic disorder those who received antipsychotic drugs like haloperidol and risperidone or olanzapine.

show abstract

Section: Methodsmentioning

confidence: 99%

The Prevalence of Metabolic Syndrome of Patients on Treatment with Haloperidol and Risperidone or Olanzapine

Suresh

Lakhani²,

Shah

et al. 2021

JPRI

View full text Add to dashboard Cite

show abstract

“…Severe mood disorders could have serious negative consequences extending to family members ( Fekadu et al, 2021 ). Moreover, the International Classification of Diseases (ICD-11) published by the World Health Organization (WHO) reveals that mental disorders include diseases of depression, bipolar illness, anxiety (e.g., panic attacks and phobias), mood-related sleep disorders, and other mood disorders (e.g., compulsive overeating) and conditions associated with post-traumatic stress disorder and more ( Krawczyk and Święcicki, 2020 ). In most cases, mild symptoms can be relieved with a combination of medications and psychotherapy.…”

Section: Introductionmentioning

confidence: 99%

Inhalation Aromatherapy via Brain-Targeted Nasal Delivery: Natural Volatiles or Essential Oils on Mood Disorders

Cui

Wei

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Mood disorders, also often referred to as affective disorders, are a group of psychiatric illnesses that severely impact mood and its related functions. The high medical expenditures have placed a significant financial burden on patients and their families. Aromatherapy is an alternative and complementary treatment that utilizes essential oils (EOs) or volatile oils (VOs) to achieve major therapeutic goals. In general, EOs are volatile chemicals that enter the body primarily through skin absorption and/or nasal inhalation. In addition, they can work through oral administration. Inhalation aromatherapy has shown unique advantages for treating mood disorders, especially depression, anxiety and mental disorders such as sleep disorder, which have been validated over the last decade through clinical and animal studies. Accumulating evidence has shown that EOs or VOs can bypass the blood-brain barrier to target brain tissue through the nasal-brain pathway. Subsequently, they act on the cerebral cortex, thalamus, and limbic system in the brain to improve symptoms of anxiety, depression and improve sleep quality. Here, we review the natural aromatic plants’ volatiles or essential oils used commonly as adjuncts to manage mood disorders and illustrate the mechanisms of inhalation aromatherapy, and mainly summarized the application of transnasal inhalation aromatherapy in depression, anxiety, and sleep disorders. We conclude that aromatherapy does not cause side-effects, which is vastly different from commonly used psychotropic drugs. Inhalation aromatherapy via brain-targeted nasal delivery offers potentially efficacious treatment for mental disorders and merits further study.

show abstract

“…[2] However, in the new classification standard of the fifth edition of DSM (DSM-V) [3], the mood disorder is regarded as two independent categories, including bipolar and bipolar related disorders, as well as depressive disorder. Accordingly, the ICD-11 [4] will also be revised to be synchronized with DSM-V.…”

Section: Introductionmentioning

confidence: 99%

Optimizing multi-domain hematologic biomarkers and clinical features for the differential diagnosis of unipolar depression and bipolar depression

Zeng

Zhang

Xiang

et al. 2022

Preprint

View full text Add to dashboard Cite

There is a lack of objective features for the differential diagnosis of unipolar and bipolar depression, especially those that can be easily accessible in practical settings. Some studies have shown that unipolar and bipolar depression have different associations with hematologic biomarkers and clinical features such as the age of onset. However, none of them have used these features for differential diagnosis. We investigated whether biomarkers of complete blood count, blood biochemical markers and clinical features could accurately classify unipolar and bipolar depression using machine learning methods.1,160 eligible patients were included in this retrospective study (918 with unipolar depression and 242 with bipolar depression). 27 biomarkers of complete blood count,17 blood biochemical markers and 2 clinical features were investigated for the classification. Patient data was split into training (85%) and test set (15%). Using ten-fold cross validation for training, logistic regression (LR), support vector machine (SVM), random forest (RF) and Extreme Gradient Boosting (XGBoost) were compared with feature selection.We calculated the AUC, sensitivity, specificity and accuracy. The optimal performance was achieved by XGBoost using a combination of selected biomarkers of complete blood count (WBC, PLR, MONO, LYMPH, NEUT Ratio, MCHC, BASO Ratio, LYMPH Ratio), blood biochemical markers (albumin, potassium, chlorine, HCT, calcium, LDL, HDL) and clinical features (disease duration, age of onset). The optimal performances achieved on the open test set were AUC 0.889, sensitivity 0.831, specificity 0.839 and accuracy 0.863. Hematologic biomarkers and onset features seem to be reliable information that could be easily accessible in clinical settings to improve diagnostic accuracy. In addition, we further analyzed the importance of specific blood biomarkers in samples of disease durations <= 3 years and > 3 years. WBC and MONO remained informative across different disease durations. Meanwhile, NEUT, BASO Ratio, HCT and LYMPH, and albumin were more indicative in the short course (<= 3 years), whereas NLR and chlorine were more indicative in the longer course (> 3 years). This may suggest that, given the overall stability of the model, longitudinal changes in biomarkers should be investigated across different disease courses and age groups.

show abstract

ICD-11 vs. ICD-10 – a review of updates and novelties introduced in the latest version of the WHO International Classification of Diseases

Cited by 46 publications

References 5 publications

The Prevalence of Metabolic Syndrome of Patients on Treatment with Haloperidol and Risperidone or Olanzapine

The Prevalence of Metabolic Syndrome of Patients on Treatment with Haloperidol and Risperidone or Olanzapine

Inhalation Aromatherapy via Brain-Targeted Nasal Delivery: Natural Volatiles or Essential Oils on Mood Disorders

Optimizing multi-domain hematologic biomarkers and clinical features for the differential diagnosis of unipolar depression and bipolar depression

Contact Info

Product

Resources

About